Shots:

• The companies collaborate to develop novel species-specific mAb biotherapeutics targeting a wide range of diseases in the veterinary species with an initial focus on dogs and cats
• The collaboration will utilize Invetx’s discovery platform- optimization technologies- and Ab expertise to develop veterinary biotherapeutics against selected targets for chronic & serious diseases in animals
• Boehringer Ingelheim will boost veterinary therapies through clinical and regulatory development to the commercialization of the products

  | Ref: Boehringer Ingelheim | Image: Franchise India